RVL Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.rvlpharma.com
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 442
- Registration Number
- NCT05179577
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
- Conditions
- Blepharoptosis
- Interventions
- Other: Vehicle ophthalmic solution
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT03565887
- Locations
- 🇺🇸
Barnet, Dulany Perkins, Phoenix, Arizona, United States
🇺🇸Orange County Ophthalmology, Garden Grove, California, United States
🇺🇸North Valley Eye, Mission Hills, California, United States
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
- Conditions
- Blepharoptosis
- Interventions
- Other: Vehicle ophthalmic solution
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT03536949
- Locations
- 🇺🇸
Barnet, Dulany Perkins, Phoenix, Arizona, United States
🇺🇸Orange County Ophthalmology Medical Group, Garden Grove, California, United States
🇺🇸North Valley Eye Medical, Mission Hills, California, United States
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT03319732
- Locations
- 🇺🇸
Neuro Pain Medical Center, Fresno, California, United States
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
- Conditions
- Spasticity, MuscleMultiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 536
- Registration Number
- NCT03290131
- Locations
- 🇧🇾
Grodno Regional Clinical Hospital, Grodno, Belarus
🇧🇾Minsk City Clinical Hospital #5, Minsk, Belarus
🇧🇾Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology, Minsk, Belarus
- Prev
- 1
- 2
- Next